

## Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension

Sofianopoulou, E; Kaptoge, S; Graf, S; Hadinnapola, C; Treacy, CM; Church, C; Coghlan, G; Gibbs, JSR; Haimel, M; Howard, L; Johnson, M; Kiely, DG; Lawrie, A; Lordan, J; MacKenzie Ross, RV; Martin, JM; Moledina, S; Newnham, Michael; Peacock, AJ; Price, L

DOI:

[10.1183/13993003.01429-2018](https://doi.org/10.1183/13993003.01429-2018)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Sofianopoulou, E, Kaptoge, S, Graf, S, Hadinnapola, C, Treacy, CM, Church, C, Coghlan, G, Gibbs, JSR, Haimel, M, Howard, L, Johnson, M, Kiely, DG, Lawrie, A, Lordan, J, MacKenzie Ross, RV, Martin, JM, Moledina, S, Newnham, M, Peacock, AJ, Price, L, Rhodes, CJ, Suntharalingam, J, Swietlik, EM, Toshner, MR, Wharton, J, Wilkins, MR, Wort, SJ, Pepke-Zaba, J, Condliffe, R, Corris, PA, Di Angelantonio, E, Provencher, S & Morrell, NW 2019, 'Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis', *The European respiratory journal*, vol. 53, no. 5, 1801429. <https://doi.org/10.1183/13993003.01429-2018>

[Link to publication on Research at Birmingham portal](#)

**Publisher Rights Statement:**

Checked for eligibility: 09/05/2019

This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.

<https://doi.org/10.1183/13993003.01429-2018>

**General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

**Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## TRAFFIC EXPOSURES, AIR POLLUTION AND OUTCOMES IN PULMONARY ARTERIAL HYPERTENSION: A UNITED KINGDOM COHORT STUDY ANALYSIS

Eleni Sofianopoulou<sup>1</sup>, Stephen Kaptoge<sup>1</sup>, Stefan Gräf<sup>2,3,4</sup>, Charaka Hadinnapola<sup>2</sup>, Carmen M. Treacy<sup>2,6</sup>, Colin Church<sup>17</sup>, Gerry Coghlan<sup>12</sup>, J. Simon R. Gibbs<sup>11</sup>, Matthias Haimel<sup>2</sup>, Luke Howard<sup>10</sup>, Martin Johnson<sup>17</sup>, David G. Kiely<sup>8</sup>, Allan Lawrie<sup>9</sup>, James Lordan<sup>7</sup>, Robert V. MacKenzie Ross<sup>18</sup>, Jennifer M. Martin<sup>2,3,4</sup>, Shahin Moledina<sup>13</sup>, Michael Newnham<sup>2</sup>, Andrew J. Peacock<sup>17</sup>, Laura Price<sup>14</sup>, Christopher J. Rhodes<sup>10</sup>, Jay Suntharalingam<sup>18</sup>, Emilia M. Swietlik<sup>2</sup>, Mark R. Toshner<sup>2</sup>, John Wharton<sup>10</sup>, Martin R. Wilkins<sup>10</sup>, Stephen J. Wort<sup>14,10</sup>, Joanna Pepke-Zaba<sup>6</sup>, Robin Condliffe<sup>8</sup>, Paul A. Corris<sup>7</sup>, Emanuele Di Angelantonio<sup>1</sup>, Steeve Provencher<sup>22</sup>, Nicholas W. Morrell<sup>2,4</sup>

1. Department of Public Health and Primary Care, Cardiovascular Epidemiology Unit, University of Cambridge, Cambridge, CB1 8RN, United Kingdom
2. Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom
3. Department of Haematology, University of Cambridge, Cambridge, CB2 0PT, United Kingdom
4. NIHR BioResource - Rare Diseases, Cambridge, CB2 0PT, United Kingdom
5. Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom
6. Royal Papworth Hospital, Papworth, CB23 3RE, United Kingdom
7. University of Newcastle, Newcastle, NE1 7RU, United Kingdom
8. Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, S10 2JF, United Kingdom
9. Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, S10 2RX, United Kingdom
10. Imperial College London, London, SW7 2AZ, United Kingdom
11. National Heart & Lung Institute, Imperial College London, London, SW3 6LY, United Kingdom
12. Royal Free Hospital, London, NW3 2QG, United Kingdom
13. Great Ormond Street Hospital, London, WC1N 3JH, United Kingdom
14. Royal Brompton Hospital, London, SW3 6NP, United Kingdom
15. Division of Genetics & Molecular Medicine, King's College London, London, WC2R 2LS, United Kingdom
16. Institute of Medical and Biomedical Education, St George's University of London, London, SW17 0RE, United Kingdom
17. Golden Jubilee National Hospital, Glasgow, G81 4DY, United Kingdom
18. Royal United Hospitals Bath NHS Foundation Trust, Bath, BA1 3NG, United Kingdom
19. Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, United Kingdom
20. Molecular and Clinical Sciences Research Institute, St George's, University of London, London, SW17 0RE, United Kingdom
21. Blizard Institute, Queen Mary University of London, London, E1 2AT, United Kingdom
22. Pulmonary Hypertension Research Group, Institut universitaire de cardiologie et de pneumologie de Québec Research Center, Laval University, Québec, G1V 4G5, Canada

## **METHODS**

### **The United Kingdom (UK) National Cohort Study**

The PAH cohort study has recruited adult prevalent and incident patients with idiopathic PAH, heritable PAH, and PAH associated with anorexigen exposure, as well as pulmonary veno-occlusive disease since January 2014. Heritable PAH was defined on the basis of a family history or the finding of a known PAH-causing mutation. All cases were diagnosed between January 2000 to February 2018 in seven specialized pulmonary hypertension centres in the UK. The diagnostic algorithm, subsequent treatments and follow-ups were based on contemporary international guidelines [21]. Baseline clinical and hemodynamic characteristics at the time of PAH diagnosis were prospectively entered. Date of diagnosis corresponded to that of confirmatory right heart catheterization.

### **Abbreviated 2015 European Society of Cardiology/European Respiratory Society risk stratification strategy**

The abbreviated version of the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) risk stratification strategy was used to categorise patients as low, intermediate or high risk (**Table S1**) using the strategy previously proposed [28]. All patients had at least three of the six listed variables available. Briefly, the cut-off values proposed in the guidelines were graded from 1 (low risk), 2 (intermediate risk) and 3 (high risk). For each patient, the sum of all grades was divided by the number of available variables and rounded to the next integer to define the risk group. Calculations were made from baseline assessments and from follow-up assessments between 3 months and 2 years after the initiation of medical therapy for PAH.

**Table S1. Variables and cut-off values used for risk stratification**

	<b>Low risk</b>	<b>Intermediate risk</b>	<b>High risk</b>
<b>WHO FC</b>	I-II	III	IV
<b>6MWD, m</b>	>440	165-440	<165
<b>BNP, ng·L<sup>-1</sup></b>	<50	50-300	>300
<b>NT-proBNP, ng·L<sup>-1</sup></b>	<300	300-1400	>1400
<b>Right atrial pressure, mmHg</b>	<8	8-14	>14
<b>Cardiac index, L·min<sup>-1</sup>·m<sup>-2</sup></b>	≥2.5	2.0-2.4	<2.0
<b>SvO<sub>2</sub>, %</b>	>65	60-65	<60

WHO FC: World Health Organization functional class; BNP: brain natriuretic peptide; NT-proBNP: N-terminal fragment of pro-brain natriuretic peptide; SvO<sub>2</sub>: mixed venous oxygen saturation.

### **Interpretation of models with logarithmic transformation**

When a variable was log transformed (i.e. PVR, PAP, CI, RAP), we interpreted the exponentiated regression coefficients [ $\exp(\beta)$ ], which corresponded to changes in the ratio of the geometric means of the outcome variable (instead of the arithmetic means when outcomes are not log transformed). For the assessment of the association between ambient air pollution (PM<sub>2.5</sub> and NO<sub>2</sub>) and haemodynamics (i.e. PVR, PAP, CI, RAP), only haemodynamic variables were log-transformed. We therefore interpreted the exponentiated regression coefficients as the expected relative changes in haemodynamics per unit increase [ $\exp(\beta \cdot \text{Unit increase})$ ] of air pollution concentrations, using a 3-unit and 10-unit increase for PM<sub>2.5</sub> and NO<sub>2</sub>, respectively (which corresponded to their interquartile ranges rounded to the nearest integer).

Conversely, for the assessment of the association between traffic exposure indicators (i.e. distance to road, road length surrounding residency) and haemodynamics (i.e. PVR, PAP, CI, RAP), both exposure and haemodynamic variables were log-transformed. We interpreted the exponentiated regression coefficients as the expected relative changes in haemodynamics when the traffic exposure indicators increased by 1.x fold (or equivalently x% change). In this

case, we assessed the expected change in haemodynamics for a 1.60 fold (or 60% percent) increase in the geometric mean of traffic indicators (corresponding to meaningful changes on these indicators). A 60% increase in the geometric mean of traffic exposure indicators approximated to 200m increases for distance to road, 0.6km increases for road length at 500m buffer zone and 1.5km increases for road length at 1km buffer zone. These values fell within the interquartile range of the traffic indicators and are presented in the legend of the respective forest plots.

## RESULTS

**Table S2. Number of patients recruited per participating centres.**

	<b>Centre</b>	<b>Counts of Patients</b>	<b>Percentage</b>
<b>1</b>	Golden Jubilee National Hospital, Glasgow	45	12%
<b>2</b>	Imperial and Hammersmith Hospital	89	29%
<b>3</b>	Newcastle Freeman Hospital	17	6%
<b>4</b>	Royal Papworth Hospital	51	16%
<b>5</b>	Royal Brompton Hospital	31	12%
<b>6</b>	Royal Free Hospital	17	6%
<b>7</b>	Sheffield Teaching Hospital-- Royal Hallamshire Hospital	51	19%
	Total	301	100%

**Table S3. Characteristics of the Study Sample Compared with Excluded Participants, due to lack of residential addresses at diagnosis**

	<b>Analysis group Same address since diagnosis (n=301)</b>	<b>Non-eligible group (n=236)</b>	<b>P value</b>
<b>Age at Diagnosis, years</b>	51±15	45±17	<0.001
<b>Female sex</b>	199(66)	167 (71)	0.292
<b>PAH type</b>			
Idiopathic	261 (87)	200 (85)	0.600
Heritable	40 (13)	36 (15)	
<b>WHO functional class</b>			
I-II	44 (15)	52 (22)	0.065
III	219 (73)	149 (63)	
IV	38 (13)	35 (15)	
<b>Transfer coefficient (KCO), %predicted</b>	73±24	71±24	0.355
<b>Pulmonary hemodynamics</b>			
Right Atrial Pressure, mm Hg	9 [7]	8 [6]	0.059
Mean pulmonary arterial pressure, mm Hg	53 [18]	53 [17]	0.984
Cardiac Index,/min per m <sup>2</sup>	2 [1]	2 [1]	0.287
Cardiac Output, L/min	4 [2]	4 [2]	0.173
Pulmonary Vascular Resistance, WU	11 [8]	11 [9]	0.390
Mixed venous oxygen saturation, %	64 ± 8	65 ± 10	0.263
<b>Prevalent/ incident cases</b>			
Incident	138 (46)	64 (28)	
Prevalent	163 (54)	169 (73)	<0.001
Missing	0 (0)	3 (1)	

Data are presented as mean±SD, n(%) or median [IQR]. Groups were compared using t-test, Mann-Whitney U Test and chi-squared independence test. Definition of abbreviations: BMP2 = bone morphogenetic protein receptor type II; SD: standard deviation; WHO: world health organization.

**TABLE S4. CHARACTERISTICS OF THE STUDY PARTICIPANTS AT DIAGNOSIS: 1) full dataset with missing data for some of the adjusting variables (N=301); 2) dataset with complete data for adjusting variables used in survival analysis (N=286); 3) dataset with complete haemodynamics and adjusting variables used in disease severity analyses (N=243) and 4) dataset with the nearest monitor analyses data available (N=135).**

	Full initial dataset (N=301)	Complete dataset with no missing data for the variables we adjusted for in the main (survival analysis) models (N=286),	Complete Dataset for disease severity analyses (N=243)	Complete Dataset, limited to cases with "nearest monitor" air pollution data (N=135)
<b>Age at Diagnosis, years</b>	51 ± 15	51 ± 15	52 ± 16	53 ± 17
<b>Female sex</b>	199 (66)	189 (66)	161 (66)	88 (65)
<b>PAH subgroup</b>				
Idiopathic	261 (87)	247 (86)	210 (86)	120 (89)
Heritable	40 (13)	39 (14)	33 (14)	15 (11)
<b>WHO functional class*</b>				
I-II	44 (15)	41 (14)	34 (14)	17 (13)
III	219 (73)	211 (74)	183 (75)	105 (78)
IV	38 (13)	34 (12)	26 (11)	13 (10)
<b>Body Mass Index, kg/m<sup>2</sup></b>	30 ± 7	30 ± 7	30 ± 7	30 ± 7
<b>Presence of emphysema on CT scan*</b>	7 (2)	6 (2)	5 (2)	3 (2)
<b>Pulmonary hemodynamics</b>				
Right Atrial Pressure, mmHg	9 [7]	8 [7]	8 [6]	8 [6]
Mean pulmonary arterial pressure, mmHg	53 [18]	53 [18]	53 [18]	52 [22]
Cardiac Index, L/min per m <sup>2</sup>	2 [1]	2 [1]	2 [1]	2 [1]
Cardiac Output, L/min	4 [2]	4 [2]	4 [2]	4 [2]
Pulmonary Vascular Resistance, Wood units	11 [8]	11 [8]	12 [8]	11 [7]
Pulmonary capillary wedge pressure, mmHg	9 ± 3	9 ± 3	9 ± 3	9 ± 3
Mixed venous oxygen saturation, %	64 ± 8	64 ± 8	64 ± 8	64 ± 8
<b>Six-minute walk distance, meters</b>	310 [203]	310 [203]	312 [208]	318 [228]
<b>Pulmonary function tests</b>				
FEV1, %predicted	84 ± 19	84 ± 19	85 ± 18	84 ± 17
Transfer coefficient (KCO), %predicted	74 ± 24	73 ± 24	73 ± 24	70 ± 23

<b>Area-level Deprivation</b>				
q1 (most deprived)	95 (32)	93 (33)	76 (31)	40 (30)
q2	68 (23)	66 (23)	56 (23)	29 (21)
q3	61 (21)	58 (20)	49 (20)	33 (24)
q4	52 (18)	51 (18)	44 (18)	23 (17)
q5	19 (6)	18 (6)	18 (7)	10 (7)
<b>Household Income</b>				
q1	41 (14)	39 (14)	33 (14)	17 (13)
q2	40 (13)	39 (14)	32 (13)	16 (12)
q3	40 (13)	39 (14)	35 (14)	22 (16)
q4	50 (17)	49 (17)	44 (18)	28 (21)
q5 (most deprived)	28 (9)	26 (9)	23 (9)	10 (7)
q6 missing category	102 (34)	94 (33)	76 (31)	42 (31)
<b>Education</b>				
Primary and Low-Secondary	62 (21)	59 (21)	47 (19)	23 (17)
Upper and Post-Secondary	124 (41)	122 (43)	102 (42)	49 (36)
Tertiary	90 (30)	81 (28)	73 (30)	52 (39)
Missing category	25 (8)	24 (8)	21 (9)	11 (8)
<b>Smoking at diagnosis, n (%)</b>				
Current smoker	22 (7)	22 (8)	19 (8)	10 (7)
Former smoker	92 (31)	86 (30)	74 (30)	39 (29)
Never smoker	46 (15)	45 (16)	34 (14)	15 (11)
Missing category	141 (47)	133 (47)	116 (48)	71 (53)
<b>Ethnicity</b>				
British	258 (86)	246 (86)	207 (85)	110 (81)
Other White	11 (4)	11 (4)	10 (4)	8 (6)
Other	31 (10)	29 (10)	26 (11)	17 (13)

Data are presented as mean±standard deviation, n(%) or median [interquartile range].


\* The percentages may not add up to 100% due to rounding.

\*\* The presence of emphysema was based on baseline chest computed tomography at the time of diagnosis.

PAH: pulmonary arterial hypertension; WHO: World Health Organization; FEV1: Forced expiratory volume in one second.





**Figure S1. Maps for 2010 annual average (A) particulate matter with aerodynamic diameter  $\leq 2.5\mu\text{m}^3$  (PM<sub>2.5</sub>) concentration and (B) nitrogen dioxide (NO<sub>2</sub>) concentration in Great Britain and respective histograms of pollutants' concentrations.**





Legend - PM<sub>2.5</sub>: particulate matter with aerodynamic diameter  $\leq 2.5\mu\text{m}^3$ , NO<sub>2</sub>: nitrogen dioxide

**Figure S2. Time series and Location of Automatic Urban and Rural Network data for (A) Particulate Matter  $\leq 2.5\mu\text{m}^3$  (PM2.5) and (B) Nitrogen Dioxide (NO2).**

**A.**




B.








# Legend - PM<sub>2.5</sub>: particulate matter with aerodynamic diameter  $\leq 2.5\mu\text{m}^3$ , NO<sub>2</sub>: nitrogen dioxide


**Figure S3. Sum of length of road, surrounding the residential addresses**




**Legend**

-  Main Road network (Motorways, A-roads)
-  Buffer zone 100m
-  Buffer zone 200m
-  Buffer zone 500m
-  Buffer zone 1km

**Figure S4** Distribution of Particulate Matter (PM<sub>2.5</sub>), by outcome in survival analysis






**Figure S5. Linear Regression Estimating the Associations between Pulmonary Haemodynamics and Traffic Air Pollution for the crude and primary analysis models.**

Primary adjusted model: The model was adjusted for age, sex, functional class, and centre. Complete-case dataset with no missing data for the haemodynamics and the variables we adjusted for (N=243).

Both exposure and haemodynamic outcomes were log-transformed. Therefore, the relative changes represent percentage change in the haemodynamics for a 60% increase in the traffic exposure indicators. A 60% increase in the geometric mean of traffic exposure indicators approximates to 200m increases for distance to road, 0.6km increases for road length (500m buffer zone) and 1.5km increases for road length (1km buffer zone).

N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP mean: mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m<sup>2</sup>, RAP: right atrial pressure, mm Hg.




**Figure S6. Linear Regression Estimating the Associations between Pulmonary Haemodynamics and Particulate Matter  $\leq 2.5\mu\text{m}$  (PM<sub>2.5</sub>) concentrations for the crude and primary analysis models.**

Primary adjusted model: The model was adjusted for age, sex, functional class, and centre.

Log-transformed outcome variables (haemodynamics). The relative changes represent percentage change in haemodynamics per 3 µg/m<sup>3</sup> (interquartile range rounded to the nearest integer) increase in PM<sub>2.5</sub> exposure.

N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP mean: mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m<sup>2</sup>, RAP: right atrial pressure, mm Hg




**Figure S7. Linear Regression Estimating the Associations between Pulmonary Haemodynamics and Nitrogen Dioxide (NO<sub>2</sub>) concentrations for the crude and primary analysis models.**

Primary adjusted model: The model was adjusted for age, sex, functional class, and centre.

Log-transformed outcome variables (haemodynamics). The relative changes represent percentage change in haemodynamics per 10 µg/m<sup>3</sup> (interquartile range rounded to the nearest integer) increase in NO<sub>2</sub> exposure.

N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP mean: mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m<sup>2</sup>, RAP: right atrial pressure, mm Hg.





**Figure S8. Multivariable Linear Regression Estimating the Associations between Pulmonary Haemodynamics and Nitrogen Dioxide (NO<sub>2</sub>) concentrations, for the further-adjusted analysis models.**

Further-adjusted model: The model was adjusted for age, sex, functional class, smoking status at diagnosis, season, deprivation, income, education, body mass index, prevalent/incident cases, presence of BMP2 gene mutation and centre.

Log-transformed outcome variables (haemodynamics). The relative changes represent percentage change in haemodynamics per 10 µg/m<sup>3</sup> (interquartile range rounded to the nearest integer) increase in NO<sub>2</sub> exposure.

N: number of observations in each model, PVR: pulmonary vascular resistance (Wood Units), PAP mean: mean pulmonary arterial pressure, mm Hg (SD), CI: cardiac index, L/min per m<sup>2</sup>, RAP: right atrial pressure, mm Hg, BMP2: bone morphogenetic protein receptor type II.